US-based biotechnology company Numerate has entered a multi-year agreement with Japan’s Takeda Pharmaceutical Company to identify and deliver multiple clinical candidates.

The clinical candidates will be generated by applying Numerate’s artificial intelligence (AI)-driven drug discovery platform, from hit finding and expansion through lead design / optimisation and absorption, distribution, metabolism and excretion (ADME) / toxicity modelling.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the deal, Numerate will carry out discovery programmes in order to identify clinical candidates for use in Takeda’s core therapeutic areas, such as oncology, gastroenterology and central nervous system (CNS) disorders.

“We expect to produce multiple clinical candidates, while also continuing to refine, validate and expand our proprietary AI-driven platform as we work across a broad range of target types and drug design challenges.”

Numerate president and chief executive officer Guido Lanza said: “This is an ideal arrangement for Numerate because our team will be working largely independently while having the opportunity to leverage Takeda’s global experience, therapeutic area insights, and unique research and development (R&D) capabilities.

“We expect to produce multiple clinical candidates, while also continuing to refine, validate and expand our proprietary AI-driven platform as we work across a broad range of target types and drug design challenges.”

Though the financial terms of the current agreement have not yet been disclosed, they include a combination of milestone payments and royalties that reflect the value of the clinical candidates being delivered.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, Numerate has collaborated with independent international pharmaceutical company Servier to design small-molecule modulators of ryanodine receptor 2 (RyR2), a target identified as physiologically significant in the treatment of cardiovascular diseases, including heart failure and arrhythmias.